You are on page 1of 10

Performance Framework (formerly Attachment A)

These are brief guidelines on how to fill out the Performance Framework template. For more detailed specifications please consult the M&E guidelines and also the Multi-Agency Monitoring & Evaluation Toolkit (2nd edition, January 2006), both available on the Global Fund website: http://www.theglobalfund.org/en/performance/monitoring_evaluation/. Programs should report only on a limited set of indicators in this framework with clear, meaningful targets. They should show clearly the number of people receiving key services, the outcomes and impact of the program and use where possible standard indicators from existing M&E and national plans.

Section

Box
Select disease

Explanation
In this box select the disease for which the Performance Framework will be prepared. By doing so, the disease specific drop-down boxes in various sections of the template will be activated. One can also choose to complete a blank version of the template which will not offer any drop-down boxes and all fields will have to be filled in manually. This section is filled in by the Secretariat during Grant negotiations.

A)

B)

Data on periods covered, disbursement requests and progress updates, reports due dates 1. Goal(s):

Goal(s) are broad and overarching statements of a desired, medium to long-term outcome of the program and should be consistent with the national disease control strategic plan. Examples : 1) Reduce malaria related mortality and morbidity in children under 5 and pregnant women, 2) Reduce HIV related mortality in the country, 3) Reduce TB incidence and mortality in the country.

2. Impact and Outcome indicators: Impact and outcome indicators related to the goal(s) should be included in this section. In the first box select whether this line will describe an outcome or an impact indicator. Under "indicator" a drop-down box with standard indicators, as specified in the Monitoring and Evaluation Toolkit , is provided. The Global Fund encourages as far as possible the use of the proposed standard indicators, however, if appropriate for the local situation, one can overwrite this drop-down box to input a country specific indicator. The selected indicators should be in line with the national disease control strategic plan and its respective M&E plan. Baselines: Baselines for impact and outcome indicators, if not available at the onset of the program, should be determined during Phase 1, i.e. the first two years of the grant. If the source of data collected is different from the source of the baseline (for more details, refer to the section on 'baselines' below), please specify in the "comments" field in the final column of the table. Targets provided for impact and outcome indicators should include the frequency of their measurement. For more details on the frequency of reporting for outcome and impact indicators refer to the Monitoring & Evaluation Toolkit p. 13, and the corresponding disease specific sections p. 30, p. 39 and p. 46. Each goal should have a set of related, more specific objectives that will permit the Program to reach the stated goal(s). These objectives should be consistent with the objectives of the national disease control strategic plan. Indicators should be numbered according to the objective to which they relate, i.e. objective 1, indicator 1 = 1.1; objective 1, indicator 2 = 1.2,; objective 2, indicator 1 = 2.1; objective 2, indicator 2 = 2.2 etc. To achieve each objective, the key services to be delivered are defined under the respective Service Delivery Area (SDA). A drop-down box lists the Service Delivery Areas contained in the Monitoring and Evaluation Toolkit which the Global Fund recommends for use. If this list does not fully reflect the existing national or proposed disease control strategy, it may be expanded by overwriting the field. It is recommended to refer to the list of indicators in the Monitoring and Evaluation Toolkit . However, if these indicators do not adequately reflect the existing disease control program and strategies, other national indicators may be used. Please do not repeat the impact and outcome indicators in this section. Baselines serve as the starting point against which the performance of the program will be measured. Baselines should take into consideration the latest available results of previous grants and/or the latest available information provided in WHO and UNAIDS reports and other valid sources. Baseline data (value, year and source) need to be provided for each indicator. In the source field a non-exhaustive choice of sources is provided in a drop-down box. If necessary other sources may be included by simply overwriting the field. Targets should be provided according to the frequency of measurement of a given indicator (please see Monitoring & Evaluation Toolkit, p. 13), i.e. quarterly or semestrial targets should be provided for the years covered by this Performance Framework and yearly targets for the outstanding years. Not all indicators need to report for each period. For targets expressed in %, clear numerators and denominators should be provided where relevant. Tick "Y" (yes) if program results are directly tied to Global Fund financing (activities are funded by the Global Fund solely). If targets described reflect results of a broader national, regional or institutional program to which Global Fund resources contribute and thus are shared targets between all donors involved, tick "N" (no). Indicators included in the same attachment can be both, either "tied" (funded soley by Global Fund resources) or "untied" (shared funding by more than one set of resources), depending on the resources supporting achievement of related targets. Baselines should generally not be included in targets, with some exceptions. They are not included if the Global Fund-supported intervention does not build on previous activties that were funded by other donors and thus starts the activities anew. Baselines are included in targets in case the Global Fund supports activities that have previously been funded by an other donor and the Global Fund ensures their continuity. It should be indicated in the drop-down box whether baselines are included in the targets or not by ticking "Y" (yes) or "N" (no). Examples for inclusion of targets in baselines : a) number of people on ARV treatment, b) number of health facilities with no stockouts of recommended anti-malaria drugs, c) number of TB patients receiving incentives. Targets should generally be cumulative, with some exceptions. It should be clearly specified in the drop-down box whether targets are a] cumulative over the program term, (i.e target is maintained or increases across program term. In that case each target is equal or greater than the previous period's target), b] cumulative annually (i.e.target is maintained or increases across one year of the program starting counting from zero each year), or c] not cumulative (i.e. only current period target is put and is independent across periods). Please note that the programmes will be evaluated against cumulative performance over the grant term even if certain indicators are reported in a non-cumulative manner. In such cases the Secretariat will cumulate the targets and results achieved at a given time and base the evaluation on this cumulative performance. Targets should generally be cumulative, but typical examples for non-cumulative reporting are TB indicators (e.g. # and % of new smear positive TB cases detected, # and % of new smear positive cases successfully treated (both usually reported cumulative annually).

Targets:

C)

3. Program Objectives:

4. Objective/Indicator numbers: 5. Service Delivery Areas:

6. Indicators:

Baselines:

Targets:

7. Directly tied / untied(shared):

8. Baselines included in targets:

9. Cumlative vs non-cumulative targets

Example: Suppose there are 500 health centers nation-wide and you propose to increase the number of health centers with consistent supplies of artemisinin-based combination therapy (ACTs) from a starting point (baseline) of 100 and increments of 100 additional heath centers supplied each year. You can choose to report this according to the following options: a) "cumulative over the program term" (baseline not included in targets) Indicator Baseline Targets Year 1 Targets year 2

Number of health facilities with consistent supplies of ACT drugs

100

Q1 25

Q2 50

Q3 75

Q4 100

Q5 125

Q6 150

Q7 175

Q8 200

b) cumulative annually (baseline not included in targets) Indicator Baseline Targets Year 1 Number of health facilities with consistent supplies of ACT drugs 100 Q1 25 Q2 50 Q3 75 Q4 100

Targets year 2 Q5 25 Q6 50 Q7 75 Q8 100

c) "not cumulative" (baseline not included in targets) Indicator Baseline Targets Year 1 Number of health facilities with consistent supplies of ACT drugs 100 Q1 50 Q2 25 Q3 8 Q4 17

Targets year 2 Q5 32 Q6 12 Q7 42 Q8 14

Regardless of the option one chooses to report on, targets need to be self-explanatory; thus please tick in the box option a), b) or c) and, if necessary, specify further in the "comments" field in the final column of the table. 10. Comments, including methods and frequency of data collection:
D)

Sources of information and/or frequency of data collection should be listed here. In case confusion on cumulative vs. non-cumulative reporting of targets and the inclusion or exclusion of baselines should persist, please provide respective explanations here. Please provide quarterly financial information for year 1 and if available for year 2. If quarterly budget information is not available for year 2, semestrial (six monthly) budget break down can be provided. Indicative budget information for the remaining years of the program should also be provided. Please note that approximately 5-10% of the grant budget should be allocated to the M&E activities. It should be invested to strengthen national systems, and sufficient resources for the evaluation and use of data included. Programs should implement the M&E strengthening tool to identify M&E gaps with partners, and document this 5-10% allocation clearly in the M&E plan.

11. Program budget

Performance Framework Year 1&2: Indicators, Targets, and Periods Covered


(formerly Attachment A)
Program Details Country: Disease: Grant number: Principal Recipient: TCHAD MALARIA TCD-708-G03-M UNDP

Malaria

Date of draft version: Date of final version: Approved by:

9-Dec-08

A. Periods covered and dates for disbursement requests and progress updates
Period 1 Period Covered: from Period Covered: to Date Progress Update due (typically 45 days after end of period) Disbursement Request ? (Y,N) Annual Report Due Date: Audit Report Due Date: 30.05.2010 30.05.2011 30.08.2010 30.08.2011
1-Mar-09 30-Jun-09 14-Aug-09 -

Period 2
1-Jul-09 30-Sep-09 14-Nov-09 -

Period 3
1-Oct-09 31-Dec-09 14-Feb-10 -

Period 4
1-Jan-10 31-Mar-10 15-May-10 -

Period 5
1-Apr-10 30-Jun-10 14-Aug-10 -

Period 6
1-Jul-10 30-Sep-10 14-Nov-10 -

Period 7
1-Oct-10 31-Dec-10 14-Feb-11 -

Period 8
1-Jan-11 28-Feb-11 14-Apr-11 M&E comments blue = no action, for confirmation only red = please provide updated information and/or clarifications General comment --all targets (and especially impact/outcome targets) should be set according to planned/budgeted data collection activities

B. Program Goal, impact and ouctome indicators


Goals:
1 2 3 Cover 100% of health facilities operating in malaria affected districts with Artemisinin based combination therapy (CTA) To increase the coverage and methods of prevention in malaria affected districts for pregnant women and children under 5 Early detection and response to malaria epidemics in districts subject to epidemics

Impact / outcome Indicator

Indicator value

Baseline Year
2008 N/A

Targets Source Year 1 Year 2


To be determined (MIS prevalence survey) 60,776 54,023 47,270 40,517

Comments* Year 4 Year 5


50% of A prevalence study (MIS) will be conducted in baseline value program year 1 so to establish the baseline value. The study will be repeated in program year 5 for an impact evaluation. The indicateur relates to high transmission zones (see M&E Toolkit) 33,764 Les donnes seront collectes rgulirement dans les sites sentinnelles afin de disposer des donnes consolides par an av

Year 3

Impact

Prevalence of malaria parasite infection

N/A

Impact

Malaria-attributed deaths in sentinel sites (10 district hospitals)

67,529

2005

PNLP

Outcome

% of U5 children (and other target group) with uncomplicated malaria correctly managed at health facilities

15.90%

2001

WHO/PNLP

20%

30%

40%

60%

80% Data for this indicator will be collected through routine supervision of the NMCP. The baseline prevalence study (MIS) will also include a question relating to this indicator. 80% --MIS in Y2 and Y5 --During the first two years 706'990 ITNs will be distributed. Under the assumption that all bednets are being used, this would correspond to a target population of 3'54'950 pregnant women and children under 5

Outcome

% of households with at least one LLIN

5.40%

2001

WHO/PNLP study

20%

Outcome

% of children U5 sleeping under an LLIN the previous night

3%

2001

WHO/PNLP

20%

80% --MIS in Y2 and Y5 --During the first two years 706'990 ITNs will be distributed. Under the assumption that all bednets are being used, this would correspond to a target population of 3'54'950 pregnant women and children under 5 80% --MIS in Y2 and Y5 --During the first two years 706'990 ITNs will be distributed. Under the assumption that all bednets are being used, this would correspond to a target population of 3'54'950 pregnant women and children under 5 80% The target denominator are all pregnant women consultating a post-natal consultation for a TT 2 (162'115 women in 2005) in "soudanienne" zone of Chad.

Outcome

% of pregnant women sleeping under an ITN the previous night

7.20%

2001

WHO/PNLP

20%

Outcome

% of pregnant women on Intermittent preventive treatment (IPT) according to national policy (specific to Sub-Saharian Africa)

0.93%

2005

Reports : MSFLuxemburg, Bongor Project.

10%

20%

40%

60%

* please specify source of measurement for indicator in case different to baseline source

C. Program Objectives, Service Delivery Areas and Indicators

Objective Number

Objective description

1 Cover 100% of health facilities operating in malaria affected districts with Artemisinin based combination therapy (CTA) 2 To increase the coverage and methods of prevention in malaria affected districts for pregnant women and children under 5 3 Early detection and response to malaria epidemics in districts subject to epidemics

Objective / Indicator Number

Service Delivery Area

Indicator Value

Baseline (if applicable) Year


2008

Targets Year1
255 100% (255/255)

Periodical targets for year 1 & 2 Year2


452 100% (452/452)

Directly tied (Y/N)

Source
PNLP

P1
0

P2
255 100%

P3
255 100%

P4
255 100%

P5
452 100%

P6
452 100%

P7
452 100%

P8
452 100% Y

Baselines Targets cumulative (Y included in over program term / Y targets - cumulative annually / (Y/N) N - not cumulative) N Y - over program term

Comments

Treatment: Prompt, effective anti-malarial treatment

Nb and % of healthcare facilities 0 that have not once reported a (0/687) stock shortage of recommended antimalarial drugs on a national scale lasting more than one week over the last three weeks Nb and % of providers trained for 0 care in accordance with the national policy Nb of people receiving anti87,000 malarial treatment (in accordance with the national policy)

Treatment: Prompt, effective anti-malarial treatment Treatment: Prompt, effective anti-malarial treatment

2007

PNLP

2006

MSFL

173 25% (173/695) 381,543

695 100% (695/695) 641,611

15 2% 0

68 9.7% 114,463

125 18% 228,926

173 25% 381,543

347 50% 64,161

521 75% 192,483

596 86% 384,967

695 100% 641,611

Y - over program term PNLP is responsible for data collection for this indicator Y - cumulative annually Il est prvue en An 1, le traitement de 381543 cas de palu
dont 233 341 pour le palu simple et 148 202 pour le palu grave. En AN 2, il est prvue le traitement de 641 611 cas de palu dont 406 840 pour le palu simple et 234 771 pour le palu grave.

Treatment: Diagnosis

Nb of rapid diagnostic tests performed

140,000

2006

MSFL

290,698

506,885

84,260

185,372

290,698

253,443

422,929

506,885

Y - cumulative annually Mme raisonnement dans les prvision des TDR. Il


ressort de l'annexe que les TDR vont couvrir environ 70% des patients qui recevront le traitement. Les TDR permettrons dconomiser les CTA en cas de test ngatif et de les offrir des personnes rellement malades. La quantit de TDR est infrieure celle des CTA du faite que la prise en charge des enfants de moins de 5 ans est systmatique pendant la priode de haute transmission. voir explication en annexe

Treatment: Diagnosis

Number of establishments 3.9%(23/687) 2006 equipped for the biological diagnosis of malaria Supportive environment: Number of meetings organized by N/A 2008 Coordination and the NMCP among all partners partnership development involved in the fight against (national, community, malaria public-private)

PNLP

PNLP

69 10% (69/687) 4

275 40% (275/687) 8

20 3% 2

44 6% 3

69 10% 4

96 14% 5

121 17,6% 6

195 28% 7

275 40% 8

Y - over program term

Y - over program term Le PNLP est charg de l'laboration des comptes rendus des runions des partenaires, Une premire runion est prvue pour le dernier trimestre 2008, aprs la signature de la subvention avec le FM

HSS (Health Systems Strengthening): Service delivery

Nb and % of districts supervised at least once per quarter by the NMCP

N/A

2008

PNLP

28 50% (28/56)

56 100% (56/56)

28 50%

28 50%

28 50%

28 50%

56 100%

56 100%

56 100%

56 100%

HSS: Information system & Operational research

Nb and % of monthly activity N/A reports of district focal points received at the central level within 15 day

2008

PNLP

252 100% (252/252)

672 100% (672/672)

66

128

190

252 100%

346

440

534

627 100%

Prevention: Insecticidetreated nets (ITNs)

Number of ITNs distributed to the 317,000 population (pregnant women and children of less than 5 years) Number of Pregnant Women N/A receiving a full course of preventive treatment according to national guidelines Number of epidemiological 0 monitoring reports of zones at the risk of epidemicity are transmitted within 7 days

2007

PNLP

353,495

706,990

212,097

353,495

617,091

706,990

Prevention: Malaria prevention during pregnancy HSS: Information system & Operational research

2,008

DSIS/PNLP

123,750

330,002

74,250

123,750

181,042

238,334

295,626

330,002

Y - cumulative annually --In year 1, values and percentages relate to 28 of the 56 districts and in year 2 to 56 districts. --Supervision activities will not cover BET region --PNLP is responsible for completion of supervisory mission reports Y - cumulative annually In year 1, values and percentages relate to 28 districts and in year 2 to 56 districts. In year 1 the denominator is 252 activity reports (28 districts multiplied by 9 months) and in year 2 the denominator is 672 reports (56 districts multiplied by 12 months). N Y - over program term In year 2, PALAT project will acquire and distribute 305 495 ITNs. In the same year, UNICEF will be provide and distribute 61 196 ITNs including 8 436 in the project zone. Y - over program term Etant donn que les mdicaments (TPI) ne seront disponibles qu'en 2009, les premires donnes ne seront collectes que pendant cette priode, Y - cumulative annually --There are 12 epidemiological surveillance centres. In year 1 the denominator is 108 reports (12 centres multiplied by 9 months) and in year 2 the denominator is 144 (12 centres multiplied by 12 months). --sentinel sites to become operational in 2009 and reporting once HF radios have been acquired N - not cumulative --12 DS in the epidemic-risk zone. Treatment will be distributed one per year, and renewed the following year

2008

PNLP

108 100% (108/108)

252 100% (252/252)

36 33%

72 67%

108 100%

36 57%

72 71%

108 86%

144 100%

Treatment: Prompt, effective anti-malarial treatment

Number and % of districts with sufficient supply of anti malaria drugs (based on estimates) to respond to epidemics within 2 weeks of detection

N/A

2008

PNLP

12 100%

12 100%

12 100%

12 100%

12 100%

12 100%

12 100%

12 100%

12 100%

D. Program Budget
Summary period budget
Human Resources Technical Assistance Training Health Products and Health Equipment Medicines and Pharmaceutical Products Procurement and Supply Management Costs Infrastruture and other Equipment Communication Materials Monitoring & Evaluation* Living Support to Clients/Target Populations Planning and Administration Overheads Other: (To be further defined to meet national budget planning Total * exclusive of any other line items listed, e.g. HR, TA, etc.

Q1 164,670 8,400 39,330 2,502 0 0 252,710 0 5,840 0 35,640 35,636


544,728

Q2 179,670 47,400 183,654 1,010,837 110,699 279,547 138,500 12,500 9,090 0 111,760 145,856
2,229,513

Q3 164,670 47,262 28,334 81,450 0 105,398 24,000 0 27,540 0 34,473 35,919


549,046

Year 1 + 2 budget break-down Q4 Q5 179,670 164,670 8,400 44,800 0 0 1,010,837 2,502 110,699 0 345,997 47,938 24,000 1,350 12,000 0 16,090 7,310 0 0 104,473 80,930 126,860 24,465
1,939,026 373,965

Q6 164,670 112,800 84,440 1,075,089 253,114 95,737 84,000 7,500 173,335 0 164,930 155,093
2,370,708

Q7 164,670 44,800 0 2,502 0 47,938 0 0 80,350 0 72,430 28,888


441,578

Q8 164,670 44,800 0 1,075,089 253,114 95,643 0 12,000 29,560 0 221,430 132,759


2,029,065

Year 1 + 2 budget
1,347,360 358,662 335,758 4,260,808 727,624 1,018,199 524,560 44,000 349,115 0 826,067 685,477 0 10,477,631

Year 3

Indicative budgets Year 4 Year 5

Service Delivery Areas Prevention: BCC - Mass media Prevention: BCC - community outreach Prevention: Condom distribution

Outcome Indicators % of young people aged 15-24 who had sex with more than one partner in the last year % of adults aged 15-49 who are HIV infected % of young people aged 15-19 who have never had sex % of adults and children with HIV still alive 12 months after initiation % of young people aged 15-24 who never had sex in of antiretroviral therapy (extend to 2, 3, 5 years as program matures) the last year of those who ever had sex Impact Indicators % of young women and men aged 15-24 who are HIV infected % of infants born to HIV infected mothers who are infected

DataSources National Health Accounts DHS/DHS+ (Demographic and Health Survey) MICS (Multiple Indicator Cluster Survey)

Prevention: Testing and Counseling

Prevention: PMTCT

Prevention: Post-exposure prophylaxis (PEP)

Prevention: STI diagnosis and treatment Prevention: Blood safety and universal precaution

% of young people aged 15-24 reporting the consistent AIS (AIDS Indicator Survey) use of a condom with non-regular sexual partners in the last year % of most-at-risk population(s) (sex workers, clients of sex workers, % of young women and men who had sex before the SAMS (Service Availibility Mapping Survey) men who have sex with men, injecting drug users) who are HIV age of 15 infected % of HIV seroprevalence among all newly registered TB patients % of adults and children who are still on treatment after BSS (Behavioral and Surveillance Survey) 6 months, 1, 2, 3, 5 years from the initiation of treatment % of injecting drug users who have adopted behaviors Sentinel surveillance that reduce transmission of HIV. % of orphaned children compared to non-orphaned Serological surveys children aged 10-14 who are currently attending school % of young people aged 15-24 reporting the use of a condom the last time they had sex with a non-regular sexual partner % of people expressing accepting attitudes towards PLWHA, of all people surveyed aged 15-49 % of female sex workers reporting the use of a condom with every client in the last month % of men who have had sex with a female sex worker in the last year % of men reporting the use of condom the last time they had anal sex with a male partner in the last 6 months Prevalence surveys

Treatment: Antiretroviral treatment (ARV) and monitoring

Treatment: Prophylaxis and treatment for opportunistic infections Care and support: Care and support for the chronically ill Care and support: Support for orphans and vulnerable children TB/HIV collaborative activities: Intensified case-finding among PLWHA TB/HIV collaborative activities: Prevention of TB disease in PLWHA TB/HIV collaborative activities: Prevention of HIV in TB patients TB/HIV collaborative activities: Prevention of opportunistic infections in PLWHA with TB TB/HIV collaborative activities: HIV care and support for HIV-positive TB patients TB/HIV collaborative activities: Provision of antiretroviral treatment for TB patients during TB treatment Supportive environment: Policy development including workplace policy Supportive environment: Strengthening of civil society and institutional capacity building Supportive environment: Stigma reduction in all settings HSS: Service delivery HSS: PAL (Practical Approach to Lung Health) HSS: Human resources HSS: Community Systems Strengthening HSS: Information system & Operational research HSS: Infrastructure HSS: Procurement and Supply management

Facility-based survey Key informant survey Specific surveys (to be defined) Civil registration systems (vital/disease specific registration) Census Health service statistics Patient register Clinical cohort follow-up studies Community services assessment Records: laboratory, patient (e.g. treatment cards), training, certification, other (to be specified) Operational research

Service Delivery Areas Improving diagnosis Standardized treatment, patient support and patient charter Procurement and supply management M&E TB/HIV MDR-TB High-risk groups HSS (beyond TB) PAL (Practical Approach to Lung Health) PPM / ISTC (Public-Public, Public-Private Mix (PPM) approaches and International standards for TB care) ACSM (Advocacy, communication and social mobilization) Community TB care Programme-based operational research

Impact Indicators TB prevalence rate TB incidence rate TB mortality rate

Outcome Indicators Case detection Treatment success rate Smear conversion rate

DataSources National Health Accounts DHS/DHS+ (Demographic and Health Survey) MICS (Multiple Indicator Cluster Survey) AIS (AIDS Indicator Survey) SAMS (Service Availibility Mapping Survey) BSS (Behavioral and Surveillance Survey) Sentinel surveillance Serological surveys Prevalence surveys Facility-based survey Key informant survey Specific surveys (to be defined) Civil registration systems (vital/disease specific registration) Census Health service statistics Patient register Clinical cohort follow-up studies Community services assessment Records: laboratory, patient (e.g. treatment cards), training, certification, other (to be specified) Operational research R&R TB system, quarterly report R&R TB system, yearly management report Other Surveillance reports, specify

Service Delivery Areas

Impact Indicators

Outcome Indicators

DataSources

Prevention: BCC - Mass media

Death rates associated with Malaria: all-cause under-5 mortality rate in highly endemic areas Incidence of clinical malaria cases (estimated and/or reported)

Prevention: BCC - community outreach

Prevention: Insecticide-treated nets (ITNs)

Anaemia prevalence in children under 5 years of age

Prevention: Malaria prevention during pregnancy Prevention: Vector control (other than ITNs) Prevention: other - specify Treatment: Prompt, effective anti-malarial treatment

Prevalence of malaria parasite infection Laboratory-confirmed malaria cases seen in heath facilities Laboratory-confirmed malaria deaths seen in health facilities Malaria-attributed deaths in sentinel demographic surveillance sites

Treatment: Home based management of malaria Treatment: Diagnosis Treatment: other - specify Supportive environment: Monitoring drug resistance Supportive environment: Monitoring insecticide resistance Supportive environment: Coordination and partnership development (national, community, public-private) Supportive environment: other - specify HSS (Health Systems Strengthening): Service delivery HSS: Human resources HSS: Community Systems Strengthening HSS: Information system & Operational research HSS: Infrastructure HSS: Procurement and Supply management HSS: other - specify

API (Annual Parasite Index) (specific to Latin America and Asia)

% of U5 children (and other target groups) with malaria/fever receiving appropriate treatment within 24 hours (community/health facility) % of U5 children (and other target group) with uncomplicated malaria correctly managed at health facilities % of U5 children (and other target groups) admitted with severe malaria and correctly managed at health facilities % of children U5 sleeping under an ITN the previous night % of households with at least one ITN % of pregnant women (and other target groups) sleeping under an ITN the previous night % of pregnant women on Intermittent preventive treatment (IPT) according to national policy (specific to Sub-Saharian Africa) % of households in malaria areas protected by IRS

National Health Accounts

DHS/DHS+ (Demographic and Health Survey)

MICS (Multiple Indicator Cluster Survey)

MIS (Malaria Indicator Survey) SAMS (Service Availibility Mapping Survey) BSS (Behavioral and Surveillance Survey) Sentinel surveillance

MOH (routine HIS or HMIS) RBM (Roll Back Malaria) Serological surveys Prevalence surveys Facility-based survey Key informant survey

Specific surveys (to be defined) Civil registration systems (vital/disease specific registration) Census Health service statistics Patient register Clinical cohort follow-up studies Community services assessment Records: laboratory, patient (e.g. treatment cards), training, certification, other (to be specified) Operational research Questionnaire